Robust Q3 Prompts Bullish Protection

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is without doubt one of the Greatest Micro-Cap Shares to Spend money on In response to Analysts.

On November 12, HC Wainwright lowered the worth goal on Voyager Therapeutics, Inc. (NASDAQ:VYGR) to $25 from $30 and stored a Purchase ranking on the shares. Per the analyst, Voyager reported sturdy Q3 outcomes, ending the quarter with $229M in money and operational runway into 2028, whereas remaining eligible for as much as $2.4B in accomplice milestones.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) not too long ago offered on the Biopharma Again to Faculty Convention organized by funding agency Citi, offering necessary updates to medicine beneath improvement. In earnings for the third quarter of 2025, launched in early November, the agency reported losses per share of $0.47, beating analyst expectations by $0.05. The income over the interval was in extra of $13 million, down near 45% in comparison with the income over the identical interval final 12 months and beating market estimates by $5.5 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology firm that focuses on human genetics for the remedy of neurological ailments.

Whereas we acknowledge the potential of VYGR as an funding, we consider sure AI shares supply higher upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.

READ NEXT: 15 Dividend Shares Paying 4%+ Yield in 2025 and 14 Greatest US Shares to Purchase for Lengthy Time period

Disclosure: None.